Coherus BioSciences Is To Takeover Surface Oncology
- June 16th, 2023
- 236 views
Coherus BioSciences, Inc. (Nasdaq: CHRS) and Surface Oncology, Inc. (Nasdaq: SURF) have entered into a definitive merger agreement where Coherus will acquire Surface Oncology in a stock for stock transaction valued at up to $65 million.
This merger will add two clinical-stage assets, SRF388 and SRF114, to Coherus' immuno-oncology pipeline.
The agreement involves Coherus issuing shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive contingent value rights (CVRs) tied to milestone and royalty-based values.
The merger is expected to have a positive financial impact, with Surface's net cash projected to strengthen Coherus' balance sheet. Additionally, the acquisition will enable pipeline prioritization and reduce R&D spending.
In pre-market, $SURF is trading at $1.01 (+36.48%), while $CHRS is trading at $5.07 (-5.94%), following the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
A Preview: Oracle, Franco-Nevada, and Asana Earnings Due
March 09th, 2025NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025
Member Login